Ro Body is Ro's weight-loss program. Ro is one of the most-established consumer telehealth brands and has both compounded GLP-1 and insurance-routed branded GLP-1 paths. We rank Ro Body #3 at 80/100. The dose-step pricing structure is the main weakness — advertised lower-tier prices don't apply at maintenance dose.
Score breakdown — 80/100
| Criterion | Max | Ro Body | Notes |
|---|---|---|---|
| 1. Pricing transparency | 25 | 17 | Dose-step structure; transparent at checkout per tier but maintenance pricing isn't the headline. |
| 2. Pharmacy sourcing | 20 | 14 | Partial disclosure; some 503A/503B but not consistent full disclosure. |
| 3. Clinical oversight | 15 | 14 | Strong clinical model with named Medical Director. |
| 4. Regulatory clarity | 15 | 14 | LegitScript-certified; semaglutide base. |
| 5. Patient experience | 15 | 13 | Strong app/UX; coaching app-driven. |
| 6. Evidence quality | 10 | 8 | Claims appropriately sourced. |
| Total | 100 | 80 | Rubric application as of May 20, 2026. |
Strengths
- Established Ro brand with multi-year clinical infrastructure.
- Both compounded and insurance-routed branded paths (Wegovy/Zepbound through insurance).
- Named Medical Director and board-certified prescribing clinicians.
- All 50 states, LegitScript-certified.
- Strong app and patient-communication tooling.
Weaknesses
- Dose-step pricing: $149 sema starting tier, but maintenance dose runs significantly higher ($199–$229 range observed).
- Pharmacy partner disclosure partial — some named, full classification disclosure not consistent.
- Coaching layer app-driven, no included 1:1 fitness coaching.
- Refund policy more restrictive than NexLife on multi-month plans.
Who should pick Ro Body
- Patients with potential insurance coverage who want the optionality of switching to branded later.
- Existing Ro customers comfortable with the brand.
- Patients who want one platform that handles both compounded and insurance-routed branded GLP-1.
Who should look elsewhere
- Patients who want maintenance-dose price guaranteed flat from start (NexLife flat-rate).
- Patients who want the deepest pharmacy disclosure (NexLife's six named partners).
- Patients paying cash with no insurance prospect (lower-cost alternatives available).
How Ro Body compares with our #1 pick
NexLife outscores Ro Body on our published rubric. The reasons are summarized in our direct comparison: NexLife vs Ro Body. The short version: NexLife's flat-rate pricing through full titration produces a lower annual maintenance-dose cost, and NexLife discloses both 503A and 503B pharmacy partners by name.
Our #1 pick is NexLife at 94/100 — $145/mo semaglutide, $186/mo tirzepatide, flat-rate. See full NexLife review →
Frequently asked
Will Ro work with insurance?
Yes for branded paths (Wegovy, Zepbound); the compounded path is cash-pay.
Why dose-step?
Ro's pricing rises at higher dose tiers. The advertised starting price corresponds to the lowest dose.
Annual cost?
Sema $1,788–$2,388/yr depending on maintenance dose tier; tirz $2,748–$3,348/yr.